Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28432562 | 0.80 | ALOX15 (0.40) | TDP1TSHRALOX15SLC29A1USP2 | |
| SCHEMBL28454907 | 0.77 | TDP1 (0.37) | TDP1TSHRALOX15SLC29A1USP2 | |
| SCHEMBL2741119 | 0.76 | TDP1 (0.64) | TDP1TSHRALOX15SLC29A1USP2 | |
| SCHEMBL28731915 | 0.75 | TDP1 (0.52) | TDP1TSHRALOX15SLC29A1USP2 | |
| SCHEMBL4957881 | 0.74 | TDP1 (0.42) | TDP1TSHRALOX15SLC29A1USP2 | |
| SCHEMBL13983364 | 0.74 | TDP1 (0.47) | TDP1TSHRALOX15SLC29A1USP2 | |
| SCHEMBL28783855 | 0.73 | MAPT (0.35) | TDP1TSHRALOX15SLC29A1MAPT | |
| SCHEMBL2235435 | 0.72 | LMNA (0.53) | SMN1; SMN2POLBKDM4EHTT | |
| SCHEMBL14301471 | 0.72 | TSHR (0.54) | TDP1TSHRALOX15SLC29A1USP2 | |
| SCHEMBL11497850 | 0.71 | ALOX15 (0.44) | TDP1TSHRALOX15SLC29A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080014157-A1 | Skin or hair treatment agents with protective effect | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-17 | — | — | US | disclosed |
| CN-101048129-A | Skin or hair treatment agents comprising 3-pyridinols and /or 5- pyrimidinols | WELLA AG (US) | 2007-10-03 | — | — | CN | disclosed |
| EP-1811950-A1 | SKIN OR HAIR TREATMENT AGENTS COMPRISING 3-PYRIDINOLS AND /OR 5- PYRIMIDINOLS | Wella AG (DE) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006050929-A1 | SKIN OR HAIR TREATMENT AGENTS COMPRISING 3-PYRIDINOLS AND /OR 5- PYRIMIDINOLS | WELLA AG (DE) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014157-A1 | Skin or hair treatment agents with protective effect | DPM1, CUTA, BHMT2 | TDP1 2057/4885TSHR 2314/4885ALOX15 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.